Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMeridian Health Plan oral antipsychotics Step Ther…
    Ask Trek AI about this page
    Currentmeridian_health_plan_of_michiganPolicy N/A

    Oral Antipsychotics Step Therapy (ANTIPSYCHOTICS - ORAL - PST)

    Customize your policy alerts

    Sign up for all meridian_health_plan_of_michigan policy alerts

    Know when meridian_health_plan_of_michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Step therapy rules governing coverage of specified oral antipsychotic and related CNS drugs for Meridian Health Plan of Michigan members; defines Step 1 and Step 2 product lists and the trial requirements to approve Step 2 agents.

    Policy Summary
    Payermeridian_health_plan_of_michigan
    PolicyOral Antipsychotics Step Therapy (ANTIPSYCHOTICS - ORAL - PST)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2025
    Last ReviewDec 1, 2025
    Next Review DateN/A
    Key ActionDocument trials of two Step 1 oral antipsychotics (or evidence of current/prior use) to approve Fanapt or Opipza; for Auvelity document a trial of a generic SSRI or SNRI plus a separate trial of bupropion unless exception applies.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~70individual products listed across steps
    Step 1 → Step 2two-tier structure
    2required Step 1 trials
    Auvelity

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    special approval conditions

    Coverage Criteria

    Step 1 trial requirement for Fanapt/Opipza

    Approve the requested Step 2 antipsychotic (Fanapt or Opipza) when the following is met:

    Fanapt/Opipza approval: Patient has tried two Step 1 drugs (oral formulations of specified antipsychotics or related agents) OR is currently taking or has taken the requested drug in the past.2 prior Step 1 trials

    A trial of the brand‑name equivalent of a generic Step 1 product counts toward this requirement.

    Auvelity approval criteria

    Approve Auvelity when ONE of the following is met:

    Auvelity approval options: (1) Patient has tried a generic SSRI OR SNRI AND separately tried bupropion; OR (2) Patient has suicidal ideation without a trial of a Step 1 drug; OR (3) Patient is currently taking Auvelity or has taken Auvelity in the past.1 of 3 options

    Explicit allowance for suicidal ideation to bypass Step 1 trial requirement.

    Provider Actions & Documentation Requirements

    Prior Authorization

    Document two Step 1 oral antipsychotic trials for Fanapt/Opipza

    Require documentation that the member has tried two distinct Step 1 oral antipsychotics (or provide evidence the member is currently taking or has previously taken the requested Step 2 drug) to authorize Fanapt or Opipza.

    • Two distinct Step 1 oral antipsychotic trials are required (brand-name of a generic Step 1 product counts).
    • Alternatively, approval may be granted if the patient is currently taking or has taken the requested Step 2 drug (Fanapt or Opipza) in the past.
    Prior Authorization

    SSRI/SNRI plus separate bupropion trial required for Auvelity

    Require documentation of a prior trial of a generic SSRI or SNRI and a separate trial of bupropion to approve Auvelity, unless the patient meets an exception (current or prior Auvelity use, or suicidal ideation).

    • Document trial of a generic SSRI OR SNRI AND a separate trial of bupropion.
    • If the patient has suicidal ideation, or is currently taking/has taken Auvelity, the SSRI/SNRI + bupropion trials are not required for approval.

    Step Therapy Requirements

    RequirementDetails / DocumentationCoverage
    Documented trials of two distinct Step 1 drugsPatient must have tried two Step 1 oral antipsychotics (oral formulations listed in policy such as aripiprazole, asenapine, brexpiprazole, cariprazine, lumateperone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, xanomeline/trospium, or ziprasidone). A trial of the brand‑name equivalent of a generic Step 1 product counts. Record drug names and trial dates.covered_with_criteria
    OR — Current or prior use of the requested Step 2 drugIf the patient is currently taking or has taken the requested Step 2 agent (Fanapt or Opipza) in the past, document prior/current use instead of two Step 1 trials.covered_with_criteria
    RequirementDetails / DocumentationCoverage
    Trial of a generic SSRI or SNRI plus a separate trial of bupropionPatient must have tried a generic SSRI OR SNRI and separately tried bupropion. Document agents used and trial dates (examples of SSRI/SNRI and bupropion products are listed in the Step 1 and Step 2 product lists).covered_with_criteria
    Exceptions: suicidal ideation or prior/current Auvelity useAuvelity may be approved without the SSRI/SNRI + bupropion trials if the patient has suicidal ideation, or if the patient is currently taking or has taken Auvelity in the past. Document rationale or prior/current use accordingly.covered_with_criteria

    Definitions

    Step 1 drugs (definitions)
    DefinitionStep 1 drugs = oral formulations of specified antipsychotics and related CNS agents (examples listed in policy: aripiprazole; asenapine maleate; brexpiprazole; cariprazine HCl; lumateperone tosylate (Caplyta); lurasidone HCl; olanzapine; paliperidone (paliperidone ER); quetiapine fumarate (IR and ER); risperidone; xanomeline/trospium chloride; ziprasidone HCl).
    ScopeStep 1 list covers multiple oral antipsychotic agents and formulations that are considered preferred first-line options for step therapy under this policy.
    Counting trialsA documented trial of the brand‑name equivalent of a generic Step 1 product counts toward the required Step 1 trials for Step 2 approval.
    Actionable requirementFor approval of certain Step 2 agents (Fanapt or Opipza), the patient must have tried two distinct Step 1 oral drugs OR be currently taking/previously taken the requested Step 2 drug.
    Examples (selected)Aripiprazole (various oral formulations); Paliperidone ER; Quetiapine (IR/ER); Brexpiprazole (Rexulti); Cariprazine (Vraylar); Lumateperone (Caplyta); Ziprasidone (oral tablets/Opipza oral film).

    Background

    This policy implements a two‑step step‑therapy approach for specified oral antipsychotic and related central nervous system agents. Products are organized into Step 1 (preferred) and Step 2 (non‑preferred) lists. For most Step 2 agents (for example, Fanapt and Opipza), coverage requires documentation that the member has tried two distinct Step 1 oral antipsychotics, or evidence that the member is currently taking or has previously taken the requested Step 2 drug. A brand‑name trial that is equivalent to a generic Step 1 product counts toward the two‑trial requirement.

    Auvelity (dextromethorphan/bupropion) is handled with a separate, specific pathway: approve when the member has tried a generic SSRI or SNRI AND separately tried bupropion, or when the member is currently taking or has taken Auvelity in the past. The policy also explicitly allows approval of Auvelity without prior Step 1 trials when the member has suicidal ideation.

    Revision History

    2025-01-01policy_effective

    Policy effective date set to 2025-01-01.

    2025-12-01policy_reviewLatest

    Policy reviewed/updated (step therapy criteria and details); document header notes update on 2025-12-01.

    Policy Summary
    Payermeridian_health_plan_of_michigan
    PolicyOral Antipsychotics Step Therapy (ANTIPSYCHOTICS - ORAL - PST)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2025
    Last ReviewDec 1, 2025
    Next Review DateN/A
    Key ActionDocument trials of two Step 1 oral antipsychotics (or evidence of current/prior use) to approve Fanapt or Opipza; for Auvelity document a trial of a generic SSRI or SNRI plus a separate trial of bupropion unless exception applies.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions & Documentation RequirementsStep Therapy RequirementsDefinitionsBackgroundRevision History
    Note

    Two-step therapy structure (Step 1 → Step 2)

    This program uses a two-step structure: drugs are assigned to Step 1 (preferred) or Step 2 (non-preferred); Step 2 coverage generally requires prior trials of Step 1 agents as specified in the criteria.

    • Step 1 lists include multiple oral antipsychotics and related CNS agents (see Step 1 product lists).
    • Step 2 lists include non-preferred agents such as Fanapt and Auvelity; Step 2 approval requires meeting the specific prior-trial requirements in the policy.
    Documentation Required

    Document evidence of two Step 1 trials for Fanapt/Opipza

    Provide documentation of two Step 1 oral antipsychotic trials (or evidence the member is currently/previously taking the requested Step 2 drug) to meet approval criteria for Fanapt or Opipza.

    • Include medication name, dosing, dates of trial, and outcome or reason for discontinuation when available.
    • A trial of the brand-name equivalent of a generic Step 1 product counts toward the requirement.
    Denial Risk

    Failure to document Step 1 trials may prevent Step 2 approval

    When Step 2 agents are requested (e.g., Fanapt, Opipza), the provider must document failure or trial of Step 1 agents — failure to do so may result in denial of the Step 2 drug request.

    • If trials of two distinct Step 1 oral antipsychotics are not documented and no current/prior use of the requested Step 2 drug is shown, authorization may be denied.
    Documentation Required

    Required documentation for Auvelity requests

    Document prior trial of a generic SSRI or SNRI AND a separate trial of bupropion, or document that the patient is currently taking or has previously taken Auvelity, or document presence of suicidal ideation when requesting Auvelity without the SSRI/SNRI + bupropion trials.

    • Include medication names, dates, and outcomes for SSRI/SNRI and bupropion trials.
    • If asserting the suicidal ideation exception, include clinical documentation supporting that presentation.
    Denial Risk

    Step 1 trial requirement for certain Step 2 drugs — denial risk

    Certain Step 2 drugs (Fanapt, Opipza) require documented trials of two Step 1 oral antipsychotics; absence of this documentation may lead to denial of the Step 2 request unless the patient is currently or was previously taking the requested Step 2 agent.

    • Ensure records show two distinct Step 1 drug trials or evidence of current/prior Step 2 use to avoid denial.
    Step 2 drugs (definitions)
    DefinitionStep 2 drugs = non‑preferred agents listed in the policy (examples include Fanapt products and Opipza [ziprasidone oral film]).
    Specific productsFanapt (iloperidone) — tablets and titration packs (1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg and titration packs A–C); Opipza (ziprasidone oral film) — 2 mg, 5 mg, 10 mg formulations.
    Approval dependencyApproval of Fanapt or Opipza requires documented trials of two distinct Step 1 oral antipsychotics unless the patient is currently taking or has taken the requested Step 2 drug in the past.
    Policy noteWhen the Step 1 trial requirement applies, evidence must show two Step 1 drug trials; failure to document these trials may prevent approval of Step 2 drugs.